Form 4: Quest Diagnostics Executive Sam Samad Acquires Additional Shares Through Dividend Reinvestment

Executive Vice President & CFO of Quest Diagnostics, Sam Samad, reports the acquisition of 21 shares of common stock through a dividend reinvestment plan.

Summary

• On July 22, 2024, Sam Samad, Executive Vice President & CFO of Quest Diagnostics, acquired 21 shares of common stock.
• The acquisition was made through a dividend reinvestment plan at a price of $146.974 per share.
• Following the transaction, Samad directly owns 17,467 shares of Quest Diagnostics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The transaction reflects a routine executive share acquisition through a dividend reinvestment plan, indicating confidence in the company's performance.

Positives

• The acquisition of shares through a dividend reinvestment plan demonstrates Samad's continued investment in Quest Diagnostics.

Industry Context

Executive share acquisitions are common and often viewed positively as they align management's interests with those of shareholders. Dividend reinvestment plans are a standard method for executives to increase their holdings.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders as it involves a small number of shares acquired through a standard dividend reinvestment plan.

Key Dates